Navigation Links
CVS Caremark Data Finds More than 50 Percent of Adults 45-years and Younger are not Adherent to Cholesterol Lowering Medications
Date:8/27/2009

WOONSOCKET, R.I., Aug. 27 /PRNewswire/ -- A study released today by CVS Caremark (NYSE: CVS) found that more than 50 percent of patients under the age of 45 who are prescribed a medication to treat high cholesterol are not optimally adherent to their therapy. In fact, the data showed that 58 percent of adults between the ages of 18-34 are not taking their cholesterol lowering medications as prescribed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )

According to the National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI), high cholesterol affects more than 65 million Americans. Because high cholesterol does not cause symptoms, individuals may not be aware that they are at increased risk of developing heart disease or experiencing a heart attack. September is National Cholesterol Education Month, and is a good opportunity for people to get their cholesterol levels checked and take steps to lower their levels if they are high.

"This data illustrates that younger adults with high cholesterol are not taking their medication as prescribed, putting them at increased risk for developing heart disease, worsening their long term clinical outcomes and ultimately increasing the cost of their care," said Troyen A. Brennan, M.D., M.P.H., Executive Vice President and Chief Medical Officer, CVS Caremark. "CVS Caremark engages plan participants with chronic diseases, such as high cholesterol, by addressing barriers to evidence-based care. We engage patients in their care early in the process by providing disease and therapy education and help them improve medication adherence through proactive intervention and outreach."

The study examined adherence to cholesterol lowering medications by evaluating de-identified data for more than 74,000 adult patients from the CVS Caremark Health Management Claims Database who incurred claims for a cholesterol lowering medication between January 1, 2008 and December 31, 2008. All study participants were continuously eligible for pharmacy benefits for the entire evaluation period. Results found that only 42 percent of patients between the ages of 18-34 were optimally adherent to their medications with a medication possession ratio (MPR) of greater than 80 percent. In addition, among those patients aged 35-44, only 50 percent were identified as optimally adherent to their high cholesterol medication.

The CVS Caremark Proactive Pharmacy Care approach engages patients earlier with education and personalized outreach to improve adherence. The Adherence to Care solution is a mail and retail based program designed to impact patient behavior through timely interventions that include face-to-face, first fill counseling; IVR and Web refill reminders, renewals and pick-up prompts; and personalized letters about the importance of staying on a prescribed therapy sent to those patients who have stopped filling a maintenance prescription and their health care provider. The Adherence to Care program has been shown to help increase adherence to high cholesterol therapies with those members under 45 years of age who participate in the program experiencing an MPR increase of more than 9 percent.

Medication possession ratio (MPR) is the standard statistic used to measure medication adherence via pharmacy claims. MPR assesses if a patient has a sufficient quantity of medication dispensed to suggest the medication is being taken as prescribed. MPR is represented as a ratio of total days supply of medication divided by the total days in the measurement period. In this study, MPR was calculated using the DMAA methodology on pharmacy claims incurred by the study subjects. Patients with an MPR greater than or equal to 80 percent were considered optimally adherent to therapy. This analysis is an observational study only, and the results demonstrate a correlation between patients under age 45 and suboptimal adherence to cholesterol lowering medications; however, as in most observational studies, the causal nature of this relationship cannot be determined.

About CVS Caremark

CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at cvscaremark.com/newsroom.

    Media Contact:
    Christine Cramer
    CVS Caremark
    Corporate Communications
    (401) 770-3317


'/>"/>
SOURCE CVS Caremark
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CVS Caremark Announces Results of 2009 Health IQ Study
2. CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients
3. CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic
4. CVS Caremark Charitable Trust Invests $300,000 in Easter Seals' Autism Services for Young Children
5. Cardinal Health Renews Distribution Agreement With CVS Caremark
6. ARTHUR(R) and CVS Caremark Debut the Winner of the ARTHUR/All Kids Can Character Search June 30 on PBS KIDS GO!(SM)
7. CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees
8. CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America
9. Video: CVS Caremark Charitable Trust Awards $4.2 Million in Grants Benefiting Children with Disabilities, Uninsured
10. CVS Caremark Launches Spanish Version of Caremark.com
11. CVS Caremark Study Documents Changes in Prescription Drug Use to Treat High Blood Pressure, High Cholesterol and Diabetes in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: